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Abstract 
One of the current challenges in the systemic delivery of nanoparticles in cancer therapy applications is the lack 
of effective tumor localization. Iron oxide nanoparticles coated with crosslinked dextran were functionalized with the 
tumor homing peptide CREKA, which binds to fibrinogen complexes in the extracellular matrix of tumors. This allows 
for the homing of these nanoparticles to tumor tissue. The iron oxide nanoparticle core allows for particle heating 
upon exposure to an alternating magnetic field (AMF) while the dextran coating stabilizes the particles in suspension 
and decreases the cytotoxicity of the system. Magnetically mediated hyperthermia (MMH) allows for the heating of 
tumor tissue to increase the efficacy of traditional cancer treatments using the iron oxide nanoparticles. While MMH 
provides the opportunity for localized heating, this method is currently limited by the lack of particle penetration into 
tumor tissue, even after effective targeted delivery to the tumor site. The CREKA-conjugated nanoparticles presented 
were characterized for their size, stability, biocompatibility, and heating capabilities. The particles were stable in PBS 
and media over at least twelve hours, had a hydrated diameter of 52 nm, and generated enough heat to raise 
solution temperatures well into the hyperthermia range (41 – 45 °C) when exposed to an AMF. Biocompatibility 
studies demonstrated that the particles have low cytotoxicity over long exposure times at low concentrations. A 
fibrinogen clotting assay was used to determine the binding affinity of CREKA-conjugated particles, which was 
significantly greater than the binding affinity of dextran, only coated iron oxide nanoparticles demonstrating the 
potential for this particle system to effectively home to a variety of tumor locations. Finally, it was shown that in vitro 
MMH increased the effects of cisplatin compared to cisplatin or MMH treatments alone.  
1. Introduction 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the United States each year 
[1]. Survival without treatment for stage IV NSCLC is 6 months if left untreated and only 9 to 12 months with 
treatment. Hyperthermia, the heating of tissue to 41-45 °C, has been shown to be effective in treating lung cancer 
when used in conjunction with radiation or chemotherapy [2-4]. While current hyperthermia treatments include 
whole body and regional hyperthermia both have several disadvantages, including the burning of healthy tissue, 
limited penetration of heat into the body, under-dosage of heat, and complications such as increased heart rate and 
increased cardiac output [5-7]. Hyperthermia treatments are further are challenged by deep seated tumors and lack 
the ability to penetrate surrounding tissues to raise the tumor tissue into the hyperthermia range [8]. Despite 
hyperthermia’s disadvantages, treatment of cancer via hyperthermia in conjunction with cisplatin has resulted in 
synergistic effects in regard to cisplatin’s efficacy [9] and sensitization of cisplatin-resistant cell lines [10]. Cisplatin (20 
µg/mL or 200 µg/mL) combined with mild incubator-induced hyperthermia at 41 °C was shown to significantly 
decrease the surviving fraction of T24 bladder cancer cells in vitro [3]. In another study completed by Hettinga and 
coworkers murine tumor cells were mutated in vitro for cisplatin resistance [10]. The cisplatin-resistant cell line was 
exposed to cisplatin (0 - 10 µg/mL) for 45 minutes at either 37 °C or 44 °C. Hyperthermia with cisplatin exposure 
resulted in a significant decrease in the percentage of cell survival of the cisplatin-resistant cells. A second 
experiment demonstrated that the cisplatin-resistant cells were sensitized by hyperthermia by pre-heating the cells 
at 44 °C for 10 minutes prior to 45 minutes of cisplatin exposure at 37 °C. This treatment sequence further decreased 
the cell survival of the cisplatin-resistant cells [10].   
In the presence of an alternating magnetic field (AMF), iron oxide magnetic nanoparticles generate heat and can 
induce hyperthermia. Magnetically-mediated hyperthermia, the heating of tissue using heat generated by magnetic 
nanoparticles in the presence of an AMF, shows great promise in overcoming the limitations of current hyperthermia 
treatments due to the ability of nanoparticles to deliver heat directly to the tumor site, therefore limiting the heat 
exposure to surrounding tissues. Iron oxide nanoparticles (IONPs) have the ability to passively or actively target 
tumors and in the presence of an external AMF, can generate heat via multiple possible loss mechanisms including 
hysteresis, Néel paramagnetic switching, and friction losses from Brownian rotation [8]. IONPs have been studied as 
imaging agents, drug delivery devices, and therapeutic enhancers due to their multitude of biological applications, 
inherent biocompatibility, magnetic properties, and lack of protein adsorption after proper coating [11]. In all these 
applications of IONPs, the main limitation to their efficacy in heating and treating solid tumors is the limitations of 
particle localization. Vascularization and the enhanced permeation and retention (EPR) effect allow for passive 
targeted delivery of nanoparticles to the periphery of solid tumors. However, active targeting through peptides or 
ligands can result in higher local concentrations of nanoparticles and lower systemic concentrations, which is 
required for more effective treatment [12].  
The proposed particle system functionalized with the peptide CREKA has the ability increase the local 
concentration of IONPs compared to non-targeted IONPs, by homing to tumor tissue. CREKA, a tumor homing 
peptide, recognizes fibrin-associated plasma proteins, which are overexpressed in cancerous tissue but not in normal, 
healthy tissue. The walls of tumor vessels and the interstitial space within tumors contain these fibrin-fibronectin 
complexes due to protein seepage from the leaky vasculature of the tumor [12].  It was shown that CREKA can 
specifically target fibrin-fibronectin complexes as demonstrated by the peptide’s lack of targeting to syngeneic B16F1 
melanoma tumors grown in mice null of fibrinogen or lacking plasma fibronectin but significant homing to syngeneic 
B16F1 melanoma tumors in wild-type mice of the same litter [13]. CREKA is a small, linear peptide of five amino 
acids, which makes it attractive to use for conjugation with nanoparticles since multiple peptides can be conjugated 
to a single nanoparticle [13]. IONPs do not require internalization into cancer cells to be effective at heating the 
tumor tissue. Therefore, CREKA conjugation to IONPs is advantageous over other peptides in that it binds to 
complexes within the tumor vasculature rather than specific integrins on the surface of cells [12]. Although this study 
focuses on CREKA-conjugated IONPs for the treatment of lung cancer, this nanoparticle system has the ability to treat 
a multitude of cancerous tumors since it recognizes fibrinogen complexes rather than specific surface integrins, 
which are often cell line dependent. CREKA can be conjugated to IONPs through the use of a short linker, N-[a-
maimidoacetoxy] succinimide ester (AMAS), which then conjugates to primary amines on the particle surface to the 
sulfhydryl group via the cysteine of CREKA. The sulfhydryl group on the cysteine is not required for fibrinogen 
binding, and can therefore be used to conjugate the peptide to the nanoparticles. By increasing the nanoparticle 
concentration within the tumor tissue by active targeting with CREKA, MMH can be more effectively administered.  
In this study, peptide-conjugated dextran-coated IONPs for enhanced tumor homing have been developed and 
characterized. Physicochemical characterization and in vitro biocompatibility studies are imperative for rationally 
develop and understanding a nanoparticle system. Prior to in vivo studies, the properties of this nanoparticle system 
such as size, stability, heating profiles, toxicity, and fibrinogen binding affinity need to be optimized. The optimal size 
for our nanoparticles is 50 nm, which will allow for tumor penetration and initial accumulation to tumor tissue via the 
EPR effect. Stability in media is an important property for systemically delivered nanoparticles, and the heating 
properties must be sufficient to induce hyperthermia conditions upon exposure to an AMF. Nanoparticle systems 
used for biological applications such as these must be screened for toxicity at low concentrations over long time 
frames, and for this specific peptide-conjugated IONP system, the binding affinity of the particles to fibrinogen 
complexes was important to verify since fibrinogen complexes within the tumor vasculature are the target of this 
system. A proof-of-concept study was then completed to show that this nanoparticle system could be used to 
enhance the effectiveness of cisplatin through magnetically mediated hyperthermia. This peptide-conjugated IONP 
has optimal physical characteristics for tumor homing via fibrin-fibronectin complexes and ideal heating capabilities, 
which can be utilized for the hyperthermia treatment of lung cancer, in combination with chemotherapy.    
2. Materials and Methods 
2.1 Materials 
Iron (III) chloride hexahydrate (FeCl3·6H2O), iron (II) chloride (FeCl2·4H2O), 9 – 11 kDa dextran, epichlorohydrin (ECH), 
cisplatin (CDDP), fibrinogen, and thrombin were obtained from Sigma Aldrich (St. Louis, MO). Ammonium hydroxide 
(NH4OH) was purchased from EMD Chemicals (Gibbstown, NJ). N-[a-maimidoacetoxy] succinimide ester (AMAS) 
linker was obtained from Thermo Scientific (Rochester, NY). CREKA peptide conjugated with 5-FAM-aminohexanoic 
acid (FAM-CREKA) was custom ordered through Biomatik (Cambridge, Ontario). Fetal bovine serum (FBS) was 
purchased from Fisher Scientific (Florence, KY). Dulbecco’s Modified Eagle Medium (DMEM), pen-strep, L-glutamine, 
Fungizone®, and sodium pyruvate were all purchased from Invitrogen (Grand Island, NY), and trypsin was purchased 
from American Type Culture Collection (ATCC, Manassas, VA). DMSO, 190 proof ethanol, PBS. All materials were used 
as received. 
2.2 Crosslinked dextran coated iron oxide nanoparticle synthesis 
A modified one-pot co-precipitation method [14] was used to prepare dextran coated IONPs. FeCl3·6H2O and 
FeCl2.4H2O were combined in a 2:1 molar ratio (2.2 grams and 0.8 grams, respectively) and dissolved in 25 mL 
deionized (DI) water and sealed in a three-neck flask under vigorous stirring and an inert nitrogen environment. 11 
grams of dextran was solubilized in 50 mL of DI water and added to the three-neck flask.  The solution was heated to 
85 °C at which 5 ml of NH4OH was injected into the vessel. The reaction was carried out for 1 hour at 85 °C.  The 
particles were centrifuged at 1000 rpm for 10 minutes to remove large agglomerates. The remaining particles were 
then dialyzed against DI water for 24 hours. Dextran coated IONPs were crosslinked using ECH for increased thermal 
stability [15]. The particle colloid (9 mL, 1 mmol Fe) was added to 9 mL 5M NaOH and 2 mL ECH. The reaction was 
carried out for 24 hours at room temperature under continuous agitation. The particle colloid was then dialyzed 
against DI water for 24 hours to remove excess ECH. Crosslinked IONPs were then aminated to allow for peptide 
conjugation. This was accomplished by reacting 0.2 mL of 30% ammonium hydroxide with the particle colloid (5 mL, 
0.2 mmol Fe) for 24 hours at room temperature under continuous agitation. The particles were then dialyzed against 
DI water for 24 hours.  
2.3 CREKA conjugation of iron oxide nanoparticles 
Amine conjugated IONPs were further conjugated with AMAS (N-[a-maleimidoacetoxyl]succinimide ester) linker. The 
primary amines on the nanoparticles react with the N-hydroxysuccinimide of the linker, and CREKA can then be 
conjugated to the particle surface by reacting the sulfhydryl group on the cysteine with the maleimide group of the 
linker. Particles were resuspended at a concentration of 1 mg Fe/mL in PBS and 2.5 mg AMAS per 2 mg Fe were 
dissolved in DMSO prior to addition to the nanoparticle suspension [13]. After the AMAS addition under vortexing, 
the reaction was carried out for 40 minutes at room temperature. Particles were then washed three times with PBS 
on 100,000 MWCO cellulose Millipore filtration columns. FAM-CREKA was then added to the particle suspension at 
25 mg per 4 mg Fe [13]. Particles were incubated overnight at 4°C and washed again with PBS. To serve as a control 
for the CREKA-conjugated IONPs, fluorescein isothiocyanate (FITC) was conjugated to amine groups on crosslinked 
dextran IONPs. FITC was added in a 1:10 molar ratio to iron oxide (0.434 mmol Fe3O4 and 0.0434 mmol FITC) and 
dissolved in 5 mL ethanol. The reaction was carried out for six hours at room temperature. The particles were then 
washed with DI water and concentrated using ultrafiltration columns. A summary of the systems investigated can be 
seen in Table 1 and a schematic of the systems synthesized can be seen in Figure 1. 
2.4 Particle characterization 
Transmission electron microscopy (TEM). TEM was completed using a JEOL 2010F system operating at 200 KeV. Iron 
oxide nanoparticles were diluted to 200 µg/mL Fe in DI water and then dried on carbon TEM grids prior to analysis.    
Ultraviolet (UV)-Visible spectroscopy. The stability of the nanoparticles was analyzed using a CaryWin 50 probe UV-
visible spectrophotometer. IONPs were diluted to 200 µg/mL Fe in PBS or DMEM with 10% FBS. Sample absorbance 
was read at 540 nm over 12 hours.  
Thermogravimetric analysis (TGA).  TGA was used to quantify the mass percent of the iron oxide core in the particle 
systems using a Netzsch Instruments STA 449A system. Approximately 5 mg of particle sample was heated at a rate 
of 5 °/minute. At 100 °C, the sample was held isothermally for 20 minutes to vaporize residual water.  The samples 
were heated at 5 °/minute until reaching 500 °C where they were held isothermally for an additional 20 minutes. The 
reported mass loss reported was the actual mass loss normalized to the initial sample mass after isothermal heating 
at 100 °C.  
Dynamic light scattering (DLS).  DLS measurements were obtained using a Beckman Coulter Delsa Nano C particle 
analyzer.  Nanoparticle solutions were diluted to 200 µg/mL and were sonicated in a water bath prior to size analysis.   
Alternating magnetic field (AMF) heating.  The nanoparticle heating profiles were obtained using a custom made 
Taylor Winfield magnetic induction source and the temperature was measured with a fiber optic temperature sensor 
(Luxtron FOT Lab Kit from LumaSense).  Nanoparticle suspensions were diluted in DI water to a concentration of 5 
mg/ml iron oxide.  One milliliter of suspension was placed in a 2 ml microcentrifuge tube and placed in the center of 
the AMF induction coil.  The suspension was heated at a field strength of 58 kA/m and 292 kHz frequency until the 
temperature of the suspension reached equilibrium. The specific absorption rate (SAR) values of the nanoparticle 
suspensions were then calculated using the initial temperature change normalized to the mass of nanoparticles 
present.  
2.5 Cytotoxicity analysis of particle systems 
A549 lung carcinoma cells obtained from ATCC were cultured from passages 5 - 10 in DMEM supplemented with 10% 
FBS, 10 μg/ml Fungizone®, 2 μg/ml penicillin-streptomycin, and 4mM L-glutamine. Cells were seeded into 96-well 
plates at 4,000 cells/well and incubated for 24 hours.  The cells were then exposed to nanoparticles in complete cell 
media at concentrations of 50, 100, 350, and 500 µg Fe/ml.  Cytotoxicity was determined using a calcein red 
fluorescent stain (1 µM, λex=540nm and λem=590nm) after 24 and 48 hours. Cell viability was analyzed using a Biotek 
SynergyMx microplate reader and the fluorescence of the cells exposed to the nanoparticle solutions was normalized 
to the fluorescence of the control cells.  
2.6 CREKA and CREKA IONP binding affinity to fibrinogen clots 
To synthesize fibrinogen clots, 75 µL of fibrinogen solution (2 mg/mL) in 0.9% NaCl was added to a 96-well plate. 30 
µL of a 2.5 U/mL thrombin solution in 0.9% NaCl was subsequently added to the same 96-well plates. The plates were 
placed in an incubator shaker at 37°C for 5 minutes, and then gels were formed after four hours incubation at 37°C. 
Binding affinity of fluorescently labeled CREKA conjugated IONPs (CREKA-IONP) was compared to the binding affinity 
of unconjugated CREKA (CREKA only) and FITC conjugated iron oxide nanoparticles without CREKA (FITC-IONP).  
CREKA-IONP and FITC-IONP systems were diluted by taking 5, 10, 25, and 50 µL of nanoparticle solution and diluting 
to a total volume of 50 µL with DI water. The exact nanoparticle concentration was not necessary due to taking the 
fluorescence ratio of the bound to free particles at the same concentration. CREKA was diluted to 50, 100, 250 and 
500 µM. 50 µL of solution (particle or CREKA only) was added to each clot. After one hour, half of samples were 
washed twice with 120 µL of DI water to remove any CREKA or IONPs not bound to the fibrinogen clots and the 
fluorescence of the plate was read on the microplate reader (λex=488 nm and λem=520 nm). The bound CREKA or FITC 
fluorescence (washed gels) was normalized to the corresponding free (unwashed gels) solution for each sample.  
2.7 In vitro magnetically mediated hyperthermia 
One mL of A549 lung carcinoma cells (passage 15) was suspended in complete cell culture media in a 1.5 ml 
microcentrifuge tube at a concentration of 300,000 cells. The vials were then centrifuged at 800 x g for 5 minutes to 
pellet the cells. The media supernatant was removed and the cells were resuspended in 1 mL of the respective 
treatment solutions. The six treatments are outlined in Table 2. Hyperthermia treatments (indicated by AMF 
exposure) lasted 30 minutes and all controls were also exposed to treatments or experimental conditions (i.e. room 
temperature) for 30 minutes. After treatment, the vials were centrifuged at 800 x g for 5 minutes, the treatment 
solution was removed, and replaced with fresh media. A second centrifugation cycle was completed to further wash 
the cells of the treatment solutions. The treated cells were then seeded into 48-well plates at 30,000 cells/mL (250 
µL/well). The viability of the cells was analyzed 48 and 72 hours post-treatment using a calcein AM assay (2 µM, 
λex=494 nm and λem=517 nm) analyzed by a microplate reader. The fluorescence of the cells exposed to the various 
treatments was normalized to the fluorescence of the control cells at each time point.  
2.8 Statistical analysis 
Statistical analysis was completed using Daniel’s XL Toolbox in Microsoft Excel. A 1-way ANOVA test was used to 
determine the statistical differences of the cytotoxicity analysis and magnetically mediated hyperthermia study. A 
student t-test was used to determine the statistical differences of the fibrinogen binding study.  
3. Results and Discussion 
3.1 Particle characterization 
The iron oxide cores of the nanoparticles exhibited diameters of 5 – 13 nm as shown by the TEM images in Figure 
2. The clustering of the iron oxide suggests that multiple cores are encapsulated by the dextran coating for each 
nanoparticle. Due to the low density of the dextran coating, no differences were observed between the TEM images 
of the Fe3O4+Dx and Fe3O4+Dx-ECH nanoparticles. As seen in Table 1, size analysis indicated that the hydrated 
diameters of the nanoparticle systems were approximately 52 nm. Particles of this size have been shown to 
extravasate into tumor tissue and have been used in passive tumor targeting by taking advantages of the leaky 
vasculature of the tumor and the enhanced permeation and retention effect [16, 17].  
Ensuring the stability of nanoparticles in various types of solutions over time is very important, especially for the 
systemic delivery of therapeutics. Particle-particle interactions can induce aggregation and particle settling which can 
adversely affect the properties of the nanoparticles, such as heating capabilities and tumor targeting. Particle 
aggregates greater than 200 nm not only settle out of solution, but also attract opsonin proteins in vivo which label 
the particles for removal through the reticuloendothelial system (RES) [16].  Through UV-visible spectroscopy it was 
shown that the nanoparticles were stable in both PBS and DMEM for each stage of particle synthesis over a time 
period of 12 hours (Figure 3). A normalized absorbance of one indicates minimal to no particle settling in solution. A 
slight increase in particle stability in PBS after crosslinking the dextran with epichlorohydrin was observed, which was 
expected due to an increase in the thermal stability of the dextran coating. Overall, these results indicate the high 
stability of the evaluated particle systems in several solutions, which may be an indication of increased particle 
stability for systemic delivery for the treatment of lung cancer using MMH. 
Thermogravimetric analysis was used to confirm the presence of the dextran coating on the iron oxide 
nanoparticles. This showed that the coating accounted for 59 - 64% of the nanoparticle mass prior to CREKA 
conjugation. The coating weight percentage was calculated by subtracting the final mass fraction from the initial 
normalized mass. As depicted in Figure 4, crosslinking of the dextran coating with ECH was confirmed by the shift of 
the mass loss profile to the right where an increase in the temperature at which the greatest mass loss occurred 
shifted from 285 °C (Fe3O4+Dx) to 306 °C, (Fe3O4+Dx-ECH and Fe3O4+Dx-ECH-Amine), indicating a greater thermal 
stability of the coating. The observed single drop in particle mass with increasing temperature confirms a single 
dextran layer on the surface of the particles, as this abrupt change in weight has been previously associated with a 
monolayer of dextran [18] . The dextran coating of the final CREKA-IONP only accounted for 30% of the nanoparticle 
mass due to the dissolution of AMAS linker in DMSO during the final CREKA conjugation process. Dextran has a very 
high affinity for DMSO resulting in any free or weakly bound dextran solubilizing in the DMSO and being washed from 
the nanoparticle system during the washing process. As indicated by UV-visible spectroscopy, the CREKA-IONP 
remained stable in PBS and DMEM indicating that dextran was still present on the surface of the particles. 
3.2 Remote controlled heating of iron oxide magnetic nanoparticles via AMF 
In the presence of an AMF (58 kA/m, 292 kHz), the iron oxide nanoparticle systems (5 mg/mL Fe3O4) heated the 
bulk solution into or above the hyperthermia range (41 - 45 °C) as seen in Figure 5. Fe3O4+Dx, Fe3O4+Dx-ECH, and 
Fe3O4+Dx-ECH-Amine particles heated to 41 °C within 300 seconds. The final CREKA-IONP system took longer to reach 
the hyperthermia range and heated to a lower final temperature than the other systems. The iron concentration of 
the nanoparticles was usually determined using an iron assay prior to dilution for heating in the AMF. However, the 
exact iron concentration of the CREKA-IONP could not be determined due to low volume of particles so the initial 
iron concentration in the CREKA-IONP prior to washing was used. Therefore, if any iron oxide nanoparticles were lost 
in the ultracentrifugation washing steps, the actual iron concentration of the AMF heating samples would be lower 
than calculated, accounting for the lower final temperature and decreased initial slope of the heating profile. SAR 
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where Cp,Fe is the heating capacity of iron, mFe the mass of iron, Cp,H2O the heating capacity of water, mH2O the mass of 
water, and dT/dt the initial slope of the heating profile. The SAR values are reported in Table 1 and indicate the 
energy being produced per gram of iron oxide. The lower SAR value for the CREKA-IONP is accounted for by the 
previous explanation of the concentration discrepancy.  
 
3.3 Cytotoxicity analysis of particles 
Cytotoxicity of the particles produced in each step in the particle synthesis was evaluated using A549 lung 
carcinoma cells. A549 cells were exposed to low doses of iron oxide nanoparticles for 24 and 48 hours, and the 
viability of the cells was analyzed using a calcein AM stain. As depicted in Figure 6, the particles exhibited no toxicity 
(at least 100% viability) after 24 hours. Dextran is colloidal, hydrophilic, water-soluble substance which is inert in 
biological systems, therefore decreasing protein adsorption to the nanoparticle surface which would lead to toxicity 
[19]. After 48 hours, the particles were still mostly non-toxic at these concentrations, however, there was a 
significant difference between the control and the CREKA-IONP at 100, 350, and 500 µg Fe/mL as determined via a 1-
way ANOVA test. However, the viability of the A549 cells after exposure to these concentrations for 48 hours is still 
above 80%, indicating that the particles are minimally toxic even though the difference from the control is significant.  
3.4 Fibrinogen binding affinity 
CREKA-IONPs were shown to bind to fibrinogen clots with a significantly greater bound-to-free fluorescence ratio 
than fluorescently tagged iron oxide nanoparticles (FITC-IONP) (Table 2). The bound-to-free fluorescence ratios of 
free CREKA and CREKA-IONPs were not significantly different, indicating that conjugation to the nanoparticle surface 
does not inhibit the binding properties of CREKA. The sulfhydryl group on the cysteine of CREKA is not required for 
binding to fibrinogen clots. Therefore, conjugation to the nanoparticle surface through a Michael addition reaction 
with an AMAS linker does not influence the fibrinogen binding properties of CREKA. These results indicate that CREKA 
can be functionalized to the IONP in order to localize the nanoparticles at the tumor site through binding with 
fibrinogen complexes in the extracellular matrix. CREKA-IONPs do not bind to specific integrins on the cell surface 
providing the opportunity to target a wider range of cancers. Additionally, CREKA-IONPs have resulted in amplified 
homing by inducing localized tumor clotting in vivo [13]. These clots then attract more CREKA-IONPs and the cycle 
continues. This amplified homing of CREKA to the fibrin complexes within the tumor, make it attractive for localizing 
high concentrations of IONPs at the tumor site for magnetically mediated hyperthermia.  
3.5 Magnetically-mediated hyperthermia 
The heating properties of the magnetic iron oxide nanoparticles were utilized to induce in vitro hypothermia 
conditions on A549 lung carcinoma and the effects of combined MMH and cisplatin treatments were evaluated since 
cisplatin is known to increase MMH efficacy at elevated temperatures [4, 20]. Five treatments plus a control were 
evaluated as seen in Table 2 and cell viability 48 and 72 hours post-treatment was determined to allow time for 
cellular response to the treatments. After 48 hours (Figure 7), there is no significant difference between MMH 
treatment alone and combined cisplatin and MMH treatment (CDDP+MMH). However, at this time point there is also 
no difference between the viability of cells exposed to cisplatin and the control, indicating that the cells have not 
responded to the cisplatin treatment. As seen in Figure 8, after 72 hours there is a significant difference (p < 0.01) 
between the viability of cells exposed to MMH treatment alone and combined cisplatin and MMH treatment 
(CDDP+MMH). At this time point, the cells have responded to the cisplatin treatment, as shown by the significantly 
decreased viability of cells exposed to cisplatin compared to the control. Additionally, cell morphology dramatically 
changes when the cells are treated with cisplatin combined with MMH compared to either treatment alone. Images 
in Figures 7 and 8, show the cell with blebs, or localized decoupling of the cytoskeleton from the cell membrane, 
which is an indicator of apoptosis, or programmed cell death [21]. Therefore, cisplatin combined with MMH has a 
significantly greater effect on cell viability than either treatment alone.  
Additional analysis was completed to determine the type of effect of MMH and cisplatin had on A549 cells after 
72 hours using the following equations [9]: synergistic, [MMH + CDDP] < [MMH] x [CDDP]/100; additive, [MMH + 
CDDP] = [MMH] x [CDDP]/100; sub-additive, [MMH] x [CDDP]/100 < [MMH + CDDP] < [MMH]; if [MMH] < [CDDP]; 
interference, [MMH] < [MMH + CDDP] < [CDDP], if [MMH] < [CDDP]; and antagonistic, [CDDP] < [MMH + CDDP], if 
[MMH] < [CDDP], where [MMH] represents the cell viability percentage exposed to magnetically mediated 
hyperthermia alone, [CDDP] represents the cell viability percentage exposed to cisplatin alone, and [MMH+CDDP] 
represents the cell viability percentage exposed to combined magnetically mediated hyperthermia and cisplatin.  72 
hours after treatment, the percent viability of the combined treatment was 23.7 ± 2.9 and [MMH] x [CDDP]/100 
equaled 26.2 ± 2.1, where the error represents standard error (n = 12). Therefore, the combined treatment of 
hyperthermia and cisplatin was determined to be additive since these values are not significantly different, as 
indicated by a student t-test. This analysis was not completed on the 48 hour post-treatment data due to the cell 
viability of cisplatin only treatment not being different from the control.  
There are several theories as to how the effects of cisplatin are enhanced by hyperthermia. Cisplatin operates by 
binding to DNA forming inter- or intra-strand crosslinks and interfering with the transcription DNA for protein 
synthesis, therefore preventing cell division, ultimately leading to cell death [22].  In vitro studies have shown that 
hyperthermia increases the intracellular concentration of cisplatin [23, 24], and therefore increases the binding of 
cisplatin to DNA [25]. Additionally, inhibition of cellular resistance to cisplatin has been observed when combined 
with hyperthermia [26]. Hyperthermia results in increased blood flow and vascular permeability allowing for greater 
drug uptake and improved oxygenation of the tumor tissue [5]. Hyperthermia has been shown to promote cell death 
by increasing the fluidity of membranes causing adverse intracellular and surface events, inactivating microtubule 
processes and by enhancing cellular antigen expression or antigen antibody complexation [27]. The efficacy of 
hyperthermia alone is not enough to replace any of the current chemotherapy standards, but its effects are sufficient 
to enhance the toxic effects of many chemotherapeutics. Therefore, by combining magnetically mediated 
hyperthermia and cisplatin, the effective dosage of cisplatin can be decreased, and therefore potentially decreasing 
the toxic side effects of the chemotherapeutic.  
4. Conclusion 
CREKA-conjugated dextran coated iron oxide nanoparticles were successfully developed and characterized for 
their use in targeted hyperthermia applications. The nanoparticles have ideal properties for systemic tumor targeting 
such as stability in cell culture media and a size of approximately 50 nm. In the presence of an alternating magnetic 
field, the particles generated sufficient heat to increase the bulk solution temperature into the hyperthermia range. 
CREKA-conjugated nanoparticles were shown to bind to fibrinogen clots with a higher affinity than FITC-conjugated 
iron oxide nanoparticles, suggesting that the nanoparticles can be effective at targeting fibrinogen overexpressed in 
tumor tissues. The binding affinity of CREKA was not inhibited by conjugation to the iron oxide nanoparticles as 
shown by similar bound-to-free ratios of fluorescence. Low concentrations of the nanoparticle systems were non-
toxic over long periods of time, indicating that the particles can be used for biological applications. When 
magnetically mediated hyperthermia was administered in conjunction with cisplatin, an enhanced cytotoxic effect 
was observed compared to cisplatin or hyperthermia alone. This peptide-conjugated nanoparticle system can be 
further studied to assess its ability to localize at tumor sites at sufficient concentrations to induce hyperthermia 
conditions upon exposure to an external alternating magnetic field.   
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Figure 1. Iron oxide nanoparticle synthesis process f
amine conjugation, and (d) conjugated with and AMAS linker, connecting the FAM
amine. 
 
Table 1. Nanoparticle systems synthesized and characterized and their abbreviations
SAR values from AMF heating. Size of Fe3O
tag but minimal difference from the other systems is expected. 
Nanoparticle System 
Dextran coated IONP 
Epichlorohydrin crosslinked dextran coated IONP
Amine-conjugated crosslinked dextran coated IONP
CREKA-conjugated dextran coated IONP (CREKA
 
Table 2. Magnetically mediated hyperthermia treatments and controls. 
Treatment Description 
Control Media only 
IONP 3 mg/mL Fe3
MMH 3 mg/mL Fe3
CDDP 100 µM cisplatin
CDDP+IONP 100 µM cisplatin plus 3 mg/mL Fe
CDDP+MMH 100 µM cisplatin plus 3 mg/mL Fe
 
or the (a) dextran coating, (b) epichlorohydrin crosslinking, (c) 
-labeled CREKA to the primary 
, size as analyzed via DLS, and 
4+Dx-ECH-Amine-CREKA via DLS could not be completed due to fluorescent 
 
Abbreviation Size (nm)
Fe3O4+Dx 52 ± 16
 Fe3O4+Dx-ECH 56 ± 11




O4 plus 30 minutes AMF exposure 
 
3O4 
3O4 and 30 minutes AMF exposure
 SAR (W/g) 
 81 ± 19 
 98 ± 16 
 89 ± 9 
 66 ± 18 
 
Figure 2. TEM images of (a) dextran coated iron oxide nanoparticles
crosslinked iron oxide nanoparticles (Fe3O
Figure 3. Normalized absorbance (at 540 nm) of 
10% v/v FBS over 12 hours using UV-visible 
Figure 4. Normalized mass loss of each nanoparticle system in the synthesis process
 
 
 (Fe3O4+Dx) and (b) dextran
4+Dx-ECH).  
the iron oxide nanoparticle systems in (a) PBS
spectroscopy. 
 
 via TGA. 
-epichlorohydrin 
 
 and (b) DMEM with 
 
Figure 5. Heating profiles of each nanoparticle system in the synthesis process
alternating magnetic field at 58 kA/m and 292 kHz (n = 3)
 
Figure 6. Normalized viability of each nanoparticle system in the synthesis process
24 hours of exposure and (b) 48 hours of exposure.  Error bars represent standard error (n
significant difference (p < 0.05) using a 1-way ANOVA test.
Table 1. Bound-to-free fluorescence for each system represented by average ± standard 
a significant difference to the CREKA-IONP 
System Bound-to-free fluorescence
CREKA only 0.69 ± 0.03 
CREKA-IONP 0.62 ± 0.03 
FITC-IONP 0.42* ± 0.04 
 
 (5 mg/mL Fe3O
. The gray box indicates the target hyperthermia range.   
 on A549 lung cancer cells after
 = 4) and * indicates a 
 
error (n
bound-to-free fluorescence ratio (p<0.05).  
 




 = 4). The * indicates 
 Figure 7. Relative viability of A549 lung cancer cells 48 hours post magnetically mediate hyperthermia treatment. 
Error bars represent standard error (n = 12
of A549 cells stained with calcein AM after 48 hours
and (f) CDDP+MMH.   
 
 
) and * indicates a significant difference (p < 0.01).  Representative images
 for: (a) Control, (b) IONP, (c)MMH, (d) CDDP
 
, (e) CDDP+IONP, 
Figure 8. Relative viability of A549 lung cancer cells 72 hours post 
Error bars represent standard error with n
images of A549 cells stained with calcein AM after 72 hours for: (a) Control, (b) IONP, (c) 
CDDP+IONP, and (f) CDDP+MMH.   
 
magnetically mediated hyperthermia 




, (d) CDDP, (e) 
